Recently, the Zhuhai Intermediate People's Court issued a judgment on the misrepresentation case of Hejia Medical (300273)** to some investors, and the court ruled in favor of the investors in the first instance.
On March 28, 2023, Hejia Medical (300273) received the "Administrative Penalty Decision" served by the Guangdong Securities Regulatory Bureau due to the violation of letter disclosure. After investigation, Hejia Medical has the following illegal facts: 1. The cumulative amount of funds occupied by related parties in 2020 is 50.2 billion yuan, in the first half of 2021, in the name of employee loans, 4.5 million yuan was transferred to the outside world, all of which were used to repay the personal debts of the controlling shareholder. 2. There are false records in Hejia Medical's 2020 annual report and 2021 annual report.
Song Lianmin (tel: 13115008800), director of Jiangsu Shengheng Law Firm, who has been engaged in ** claim cases**, said that according to the provisions of the ** Law and the relevant judicial interpretations of the Supreme Court, if the information disclosure obligor discloses false statements, resulting in losses suffered by investors in the ** transaction, the information disclosure obligor shall bear the liability for compensation.
Although Hejia Medical has been delisted, lawyer Song Lianmin said that all injured investors who **Hejia Medical** between January 3, 2020 and March 20, 2022**, and still hold the ** on March 20, 2022**, can register their claims. (The final result is subject to the people's court's determination.) ）
Hejia Medical has a total of 7 core subsidiaries. The number of products is 17 (including 14 products of the company), and the product categories cover 7 categories of medical device products, 11 first-class product categories and 16 second-level product categories. Among them, the number of class products is 1, the number of class products is 10, and the number of class products is 6.
In 2022, the total revenue of Zhuhai Hejia Medical Equipment Co., Ltd. will reach 25.2 billion yuan, a year-on-year decrease of 660% and operating costs of 20.1 billion yuan, net profit -152.5 billion yuan.